Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Confusion continues at CROI over triple nuke therapy (amended)

Triple nucleoside combinations came under more scrutiny this week at the Eleventh Conference on Retroviruses and Opportunistic Infections, with still little consenus about why so

Published
11 February 2004
By
Edwin J. Bernard
PEP for sexual exposure to HIV not 100% effective

One per cent of individuals receiving post-exposure prophylaxis (PEP) after a possible sexual exposure to HIV went on to become infected with the virus, according

Published
10 February 2004
By
Michael Carter
Opportunities and challenges on the route to effective microbicides

A plenary presentation at the Eleventh Conference on Retroviruses and Opportunistic Infections in San Francisco by Dr Robin Shattock from St George’s Hospital Medical School,

Published
10 February 2004
By
Julian Meldrum
HAART clinically and immunologically effective in babies but high rate of virologic failure

A HAART regimen consisting of d4T (stavudine, Zerit), ddI (didanosine, Videx / VidexEC) and nelfinavir (Viracept) is clinically and immunologically effective when initiated in babies

Published
09 February 2004
By
Michael Carter
Tarnished glitazones fail to reverse fat wasting

A new study published in The Lancet has dashed hopes that a class of drugs used to treat diabetes – the glitazones – may reduce

Published
09 February 2004
By
Megan Nicholson
Allergic reaction to abacavir reported after treatment break, one year after starting the drug

A woman has developed a hypersensitivity reaction to the nucleoside analogue abacavir (Ziagen) after restarting the drug after a treatment break. Investigators reporting the case

Published
06 February 2004
By
Michael Carter
Nevirapine should not be used for PEP confirms US review

HIV-negative people appear to have a higher risk of side-effects when exposed to nevirapine, according to a review of case reports and toxicity reports from

Published
02 February 2004
By
Edwin J. Bernard
New warning about nevirapine liver toxicities issued by manufacturer

Boehringer Ingelheim, the manufacturer of the non-nucleoside reverse transcriptase inhibitor (NNRTI) nevirapine (Viramune) has issued important new safety information in a letter to doctors in

Published
30 January 2004
By
Michael Carter
Vatican accuses drug companies of genocide

The Vatican has become embroiled in the battle to reduce the cost of anti-HIV medications, after a Vatican spokesman yesterday accused drug companies of “genocide”

Published
30 January 2004
By
Edwin J. Bernard
Meta-analysis finds PI-based HAART better than NNRTI regimens in NRTI experienced

Protease inhibitor (PI)-based highly active antiretroviral therapy (HAART) regimens are superior to non-nucleoside reverse transcriptase inhibitor (NNRTI)-based triple combinations, according to a meta-analysis of 14

Published
30 January 2004
By
Michael Carter

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.